(hyaluronidase (recombinant, human) + immune globulin (human))

Trials studying (hyaluronidase (recombinant, human) + immune globulin (human))

• phase3A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseasescompletedn=65
• phase3A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)recruitingn=59
• phase1A Study of TAK-881 and HyQvia in Healthy Adultscompletedn=30
• phase3Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDPcompletedn=85
• phase1A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participantscompletedn=51
• phase3Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjectscompletedn=44
• phase3A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)completedn=138